Researchers from Children’s Hospital of Philadelphia presented data from a study that linked variants in DNA methyltransferase 1-associated protein 1 (DMAP1) to a novel neurodevelopmental disorder.
Anoat Therapeutics has raised €2 million (US$2.17 million) in seed funding to develop novel therapies for cystic fibrosis. The financing comes from a seed funding partnership between Adbio Partners SAS and Inserm Transfert SA.
Incretin mimetics have revolutionized the treatment of obesity and type 2 diabetes. These therapies have shown remarkable efficacy in promoting weight loss and improving glucose metabolism and cardiometabolic health. However, a significant drawback of these therapies is the concurrent loss of lean body mass (LBM), which can account for a substantial overall weight reduction (15% to 40%). The reduction in LBM affects resting metabolic rate, often leading to a weight loss plateau and other negative outcomes.
To address the absence of clinical trials evaluating immunotherapeutics for Acinetobacter baumannii infections, a team from the University of Texas at San Antonio conducted a study using immunoinformatics (EigenBio’s proprietary epitope prediction software) to identify peptides that contain both putative B- and T-cell epitopes from proteins associated with the pathogenesis of A. baumannii.
The NLRP3 inflammasome is a multiprotein complex that plays a pivotal role in regulating the innate immune system and inflammatory signaling. Upon activation by pathogen-associated molecular patterns (PAMPs), NLRP3 oligomerizes and activates caspase-1 which initiates the processing and release of pro-inflammatory cytokines IL-1β and IL-1 that are overproduced in many inflammatory disease conditions.
New isoindolines acting as mismatch repair endonuclease PMS2 inhibitors have been reported in a Neophore Ltd. patent as useful for the treatment of cancer.
Geode Therapeutics Inc. and Xtalpi Inc. have jointly developed phosphatidylinositol 3-kinase γ (PI3Kγ) inhibitors reported to be useful for the treatment of cancer.
Recent Kallyope Inc. patents report AMP-activated protein kinase (AMPK) activators potentially useful for the treatment of allergy, cancer, depression, diabetes type 2, nutrition disorders, obesity, psoriasis, inflammatory bowel disease, metabolic syndrome, nonalcoholic steatohepatitis, Alzheimer’s and Parkinson’s disease, among others.
Research at Kumquat Biosciences Inc. has led to the development of Hetero-atom containing compounds described as tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and (PTPN2; TCPTP) inhibitors and reported to be useful for the treatment of cancer.